Low dose fluphenazine decanoate in maintenance treatment of schizophrenia.
To test the clinical efficacy of low dose fluphenazine decanoate (1.25 mg to 5.0 mg biweekly), we carried out two separate experiments: (1) an open trial in 57 schizophrenic outpatients, lasting 6 months; (2) a double-blind, placebo-controlled discontinuation study in a subgroup of patients who maintained good remission throughout the entire 6-month open trial. The results suggest that lower doses of fluphenazine decanoate than those usually used may be effective in preventing psychotic relapse while keeping total cumulative dosage to a minimum.
D000359:Aftercare; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005476:Fluphenazine / Q000627:therapeutic use*; D006801:Humans; D012008:Recurrence; D012559:Schizophrenia / Q000188:drug therapy*
D005476:Fluphenazine